---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-109809"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-09-23T11:10:29+00:00"
generated_at: "2026-09-23T11:15:28.160660+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata receives $3.7M additional DoW funding for AP-SA02 Phase 3; total $32.4M

## Summary
- Received $3.7M non-dilutive funding from U.S. Department of War for AP-SA02 Phase 3 development.
- Cumulative DoW funding under award now $32.4M, adding to $28.7M previously provided.
- Funding supports adjunctive treatment for complicated S. aureus bacteremia (MSSA/MRSA).

## SEC filing metadata
- accession: 0001104659-26-109809
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-09-23T11:10:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/0001104659-26-109809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/tm2625977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-109809
- JSON: https://secwatch.observer/filing/0001104659-26-109809.json
- Plain text: https://secwatch.observer/filing/0001104659-26-109809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.